- Home
- IGA vs MDXH Comparison
IGA vs MDXH Comparison
Compare IGA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGA
- MDXH
- Stock Information
- Founded
- IGA 2005
- MDXH 2003
- Country
- IGA United States
- MDXH Belgium
- Employees
- IGA N/A
- MDXH N/A
- Industry
- IGA Investment Managers
- MDXH
- Sector
- IGA Finance
- MDXH
- Exchange
- IGA Nasdaq
- MDXH Nasdaq
- Market Cap
- IGA 151.6M
- MDXH 141.1M
- IPO Year
- IGA N/A
- MDXH 2021
- Fundamental
- Price
- IGA $9.94
- MDXH $3.90
- Analyst Decision
- IGA
- MDXH Buy
- Analyst Count
- IGA 0
- MDXH 1
- Target Price
- IGA N/A
- MDXH $6.00
- AVG Volume (30 Days)
- IGA 42.3K
- MDXH 158.9K
- Earning Date
- IGA 01-01-0001
- MDXH 11-05-2025
- Dividend Yield
- IGA 8.93%
- MDXH N/A
- EPS Growth
- IGA N/A
- MDXH N/A
- EPS
- IGA N/A
- MDXH N/A
- Revenue
- IGA N/A
- MDXH $98,953,000.00
- Revenue This Year
- IGA N/A
- MDXH $24.40
- Revenue Next Year
- IGA N/A
- MDXH $22.29
- P/E Ratio
- IGA N/A
- MDXH N/A
- Revenue Growth
- IGA N/A
- MDXH 22.56
- 52 Week Low
- IGA $7.77
- MDXH $1.35
- 52 Week High
- IGA $8.88
- MDXH $3.91
- Technical
- Relative Strength Index (RSI)
- IGA 55.20
- MDXH 68.73
- Support Level
- IGA $9.87
- MDXH $3.46
- Resistance Level
- IGA $10.01
- MDXH $3.80
- Average True Range (ATR)
- IGA 0.09
- MDXH 0.17
- MACD
- IGA 0.00
- MDXH -0.01
- Stochastic Oscillator
- IGA 63.70
- MDXH 94.74
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.